Cohance Lifesciences (formerly Suven Pharma) ek leading CDMO/CRDMO company hai jo global pharma companies ko drug development se lekar commercial manufacturing tak end-to-end support deti hai. Company ka core focus high-margin Pharma CDMO segment par hai, jahan strong pipeline (Phase-3 aur commercial molecules) future growth ka major driver hai.
Company aggressively high-growth segments jaise ADC (Antibody Drug Conjugates) aur Oligonucleotides me expand kar rahi hai, jo next-generation pharma technologies represent karte hain. Global client base, strong R&D capabilities aur strategic acquisitions ke through company apni positioning ko strengthen kar rahi hai.
FY26 me performance weak rahi due to timing issues jaise destocking, regulatory challenges aur customer delays, lekin management ke according yeh temporary factors hain. FY27 se growth recovery expected hai aur long-term me company apne $1 billion revenue target (FY30) ko achieve karne ke liye committed hai.
Growth Drivers:
👉 Strong pipeline – Phase 3 molecules future revenue denge
👉 High-growth segments – ADC, Oligo (next-gen pharma)
👉 Global clients – sticky relationships
👉 M&A + capex – scale + technology boost
Current Issue:
👉 FY26 me slowdown – destocking, patent expiry, delays
👉 BUT business fundamentals strong hai
For more details, click the link below.
Cohance Lifescience Research Report
